Dr Martens drops despite results in line with forecasts

Dr Martens shares fell nearly 7% to 76p after H1 results that were in line with expectations as investors focused on a US tariff headwind; revenue for the 26 weeks to Sept. 28 was £322m (down 0.8% y/y, up 0.8% CER), full‑price DTC sales rose 6%, and gross margin improved 130bp to 65.3%. The group narrowed its adjusted pre‑tax loss to £9.2m (from £16.6m), cut net bank debt to £154.3m and declared an interim dividend of 0.85p, citing product innovation and tighter promotional discipline as drivers. Management says it can mitigate roughly half of a high‑single‑digit million‑pound tariff hit and remains on track for full‑year guidance (sell‑side PBT forecasts £53m–£60m); operational gains in volumes and US growth support the recovery, but tariffs and near‑term sentiment are weighing on the stock.

Analysis

Dr Martens shares fell about 7% to 76p after H1 results that were broadly in line with market expectations, with revenue for the 26 weeks to 28 September at £322m (down 0.8% y/y, up 0.8% on a constant currency basis). The market reaction focused on a disclosed high single‑digit million‑pound US tariff headwind despite management saying mitigation will offset roughly half of that impact.

Operationally the business shows trend improvements: full‑price direct‑to‑consumer sales rose 6%, overall DTC was flat, gross margin expanded 130 basis points to 65.3%, and Peel Hunt highlights a 33% increase in shoe volumes and 6% CER growth in the US; adjusted pre‑tax loss narrowed to £9.2m (from £16.6m) and net bank debt fell to £154.3m (from £186.8m). Management cites product innovation and tighter promotional discipline as drivers and declared a 0.85p interim dividend.

Guidance remains intact with sell‑side adjusted PBT forecasts of £53m–£60m and management stating the downgrade related only to tariffs; principal near‑term risks are the realisation of tariff mitigation, consumer caution through peak trading weeks, and conversion of the spring/summer 2026 order book into sales.

Key Decisions for Investors

• Consider adding a measured position on this dip given margin improvement, volume growth and lower net debt, but size the position conservatively until tariff mitigation is evidenced
• Monitor two catalysts before increasing exposure: confirmation of the effective dollar impact of US tariffs and sequential updates on DTC full‑price sales and order book conversion for spring/summer 2026
• Protect short‑term exposure with stop‑losses or hedges because consumer caution and an unmitigated tariff hit could prompt further downside despite operational progress
• Treat the 0.85p interim dividend and improved cash generation as supportive for a constructive medium‑term view, but avoid full conviction until FY profit delivery aligns with sell‑side guidance of £53m–£60m